Octa-arginine-modified pegylated liposomal doxorubicin: An effective treatment strategy for non-small cell lung cancer

Cancer Letters

Volumn 335, Issue 1, 2013, Pages 191-200

  Biswas, Swati ^a   Deshpande, Pranali P ^a   Perche, Federico ^a   Dodwadkar, Namita S ^a   Sane, Shailendra D ^a   Torchilin, Vladimir P ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Doxorubicin; Liposomes; Lung cancer; Octa arginine; Spheroids; Tumor

Indexed keywords

1,2 DIOLEOYL SN GLYCERO 3 PHOSPHOETHANOLAMINE; CASPASE 3; CASPASE 7; CELL PENETRATING PEPTIDE; COPOLYMER; DOXORUBICIN; DRUG CARRIER; LACTATE DEHYDROGENASE; MACROGOL; OCTAARGININE PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; DOXORUBICIN; HUMANS; L-LACTATE DEHYDROGENASE; LUNG NEOPLASMS; MICE; MICE, NUDE; SPHEROIDS, CELLULAR; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878451456     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.02.020     Document Type: Article

References (56)

1. Le Chevalier T. Non-small cell lung cancer: the challenges of the next decade. Front. Oncol. 2011, 1:29.
2. Lopez-Gonzalez A., Ibeas Millan P., Cantos B., Provencio M. Surveillance of resected non-small cell lung cancer. Clin. Transl. Oncol. 2012.
3. Novello S., Le Chevalier T. Chemotherapy for non-small-cell lung cancer. Part 1: early-stage disease. Oncology 2003, 17:357-364. (Williston Park).
4. Nagano T., Kim Y.H., Goto K., Kubota K., Ohmatsu H., Niho S., Yoh K., Naito Y., Saijo N., Nishiwaki Y. Re-challenge chemotherapy for relapsed non-small-cell lung cancer. Lung Cancer 2010, 69:315-318.
5. Mountain C.F. A new international staging system for lung cancer. Chest 1986, 89:225S-233S.
6. Pairolero P.C., Williams D.E., Bergstralh E.J., Piehler J.M., Bernatz P.E., Payne W.S. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann. Thorac. Surg. 1984, 38:331-338.
7. Molina J.R., Adjei A.A., Jett J.R. Advances in chemotherapy of non-small cell lung cancer. Chest 2006, 130:1211-1219.
8. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311 (1995) 899-909.
9. Harpole D.H., Herndon J.E., Wolfe W.G., Iglehart J.D., Marks J.R. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res. 1995, 55:51-56.
10. Johnstone D.W., Byhardt R.W., Ettinger D., Scott C.B. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 2002, 54:365-369.
11. Alberg A.J., Ford J.G., Samet J.M. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines. Chest 2007, 132:29S-55S. (second ed.).
12. Ohe Y., Ohashi Y., Kubota K., Tamura T., Nakagawa K., Negoro S., Nishiwaki Y., Saijo N., Ariyoshi Y., Fukuoka M. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-Arm cooperative study in Japan. Ann. Oncol. 2007, 18:317-323.
13. Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., Kalman L., Miller V., Lee J.S., Moore M., Gandara D., Karp D., Vokes E., Kris M., Kim Y., Gamza F., Hammershaimb L. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J. Clin. Oncol. 2000, 18:2354-2362.
14. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., Levitan N., Gressot L., Vincent M., Burkes R., Coughlin S., Kim Y., Berille J. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 2000, 18:2095-2103.
15. Joss R.A., Alberto P., Obrecht J.P., Barrelet L., Holdener E.E., Siegenthaler P., Goldhirsch A., Mermillod B., Cavalli F. Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide. Cancer Treat. Rep. 1984, 68:1079-1084.
16. Koukourakis M.I., Romanidis K., Froudarakis M., Kyrgias G., Koukourakis G.V., Retalis G., Bahlitzanakis N. Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer: excellent tolerance using subcutaneous amifostine for cytoprotection. Brit. J. Cancer 2002, 87:385-392.
17. A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study). The Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan). Eur. J. Surg. Oncol. 21 (1995) 69-77.
18. Octavia Y., Tocchetti C.G., Gabrielson K.L., Janssens S., Crijns H.J., Moens A.L. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J. Mol. Cell. Cardiol. 2012, 52:1213-1225.
19. Peng X., Chen B., Lim C.C., Sawyer D.B. The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine. Mol. Interv. 2005, 5:163-171.
20. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145-160.
21. Torchilin V.P. Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp. Pharmacol. 2010, 3-53.
22. Torchilin V.P. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu. Rev. Biomed. Eng. 2006, 8:343-375.
23. Barenholz Y. Doxil® - the first FDA-approved nano-drug: lessons learned. J. Control. Release 2012, 160:117-134.
24. Biswas S., Dodwadkar N.S., Sawant R.R., Koshkaryev A., Torchilin V.P. Surface modification of liposomes with rhodamine-123-conjugated polymer results in enhanced mitochondrial targeting. J. Drug Target 2011, 19:552-561.
25. Biswas S., Dodwadkar N.S., Deshpande P.P., Torchilin V.P. Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo. J. Control. Release 2012, 159:393-402.
26. Biswas S., Dodwadkar N.S., Piroyan A., Torchilin V.P. Surface conjugation of triphenylphosphonium to target poly(amidoamine) dendrimers to mitochondria. Biomaterials 2012, 33:4773-4782.
27. Gupta B., Levchenko T.S., Torchilin V.P. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv. Drug Deliv. Rev. 2005, 57:637-651.
28. Torchilin V.P. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv. Drug Deliv. Rev. 2008, 60:548-558.
29. Torchilin V.P. Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Biopolymers 2008, 90:604-610.
30. Sawant R., Torchilin V. Intracellular transduction using cell-penetrating peptides. Mol. Biosyst. 2010, 6:628-640.
31. Koshkaryev A., Piroyan A., Torchilin V.P. Bleomycin in octaarginine-modified fusogenic liposomes results in improved tumor growth inhibition. Cancer Lett. 2012, .
32. Khalil I.A., Kogure K., Futaki S., Hama S., Akita H., Ueno M., Kishida H., Kudoh M., Mishina Y., Kataoka K., Yamada M., Harashima H. Octaarginine-modified multifunctional envelope-type nanoparticles for gene delivery. Gene Ther. 2007, 14:682-689.
33. Zhang C., Tang N., Liu X., Liang W., Xu W., Torchilin V.P. SiRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J. Control. Release 2006, 112:229-239.
34. Furukawa R., Yamada Y., Takenaga M., Igarashi R., Harashima H. Octaarginine-modified liposomes enhance the anti-oxidant effect of Lecithinized superoxide dismutase by increasing its cellular uptake. Biochem. Biophys. Res. Commun. 2011, 404:796-801.
35. Khalil I.A., Kogure K., Futaki S., Harashima H. High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J. Biol. Chem. 2006, 281:3544-3551.
36. Torchilin V.P., Levchenko T.S., Lukyanov A.N., Khaw B.A., Klibanov A.L., Rammohan R., Samokhin G.P., Whiteman K.R. P-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim. Biophys. Acta 2001, 1511:397-411.
37. Allen T.M., Sapra P., Moase E. Use of the post-insertion method for the formation of ligand-coupled liposomes. Cell. Mol. Biol. Lett. 2002, 7:889-894.
38. Ishida T., Iden D.L., Allen T.M. A combinatorial approach to producing sterically stabilized (stealth) immunoliposomal drugs. FEBS Lett. 1999, 460:129-133.
39. Koren E., Apte A., Jani A., Torchilin V.P. Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. J. Control. Release 2012, 160:264-273.
40. Yang T.M., Barbone D., Fennell D.A., Broaddus V.C. Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids. Am. J. Respir. Cell Mol. Biol. 2009, 41:14-23.
41. Perche F., Torchilin V.P. Cancer cell spheroids as a model to evaluate chemotherapy protocols. Cancer Biol. Ther. 2012, 13.
42. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., Zhu J., Johnson D.H. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl. J. Med. 2002, 346:92-98.
43. Otterson G.A., Villalona-Calero M.A., Hicks W., Pan X., Ellerton J.A., Gettinger S.N., Murren J.R. Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer. Clin. Cancer Res. 2010, 16:2466-2473.
44. Seymour L.W., Ferry D.R., Kerr D.J., Rea D., Whitlock M., Poyner R., Boivin C., Hesslewood S., Twelves C., Blackie R., Schatzlein A., Jodrell D., Bissett D., Calvert H., Lind M., Robbins A., Burtles S., Duncan R., Cassidy J. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int. J. Oncol. 2009, 34:1629-1636.
45. Tsoutsou P.G., Froudarakis M.E., Bouros D., Koukourakis M.I. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC). Anticancer Res. 2008, 28:1349-1354.
46. Weiss R.B. The anthracyclines: will we ever find a better doxorubicin?. Semin. Oncol. 1992, 19:670-686.
47. Gabizon A., Shmeeda H., Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 2003, 42:419-436.
48. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., Martin F., Huang A., Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994, 54:987-992.
49. Fretz M.M., Penning N.A., Al-Taei S., Futaki S., Takeuchi T., Nakase I., Storm G., Jones A.T. Temperature-, concentration- and cholesterol-dependent translocation of l- and d-octa-arginine across the plasma and nuclear membrane of CD34+ leukaemia cells. Biochem. J. 2007, 403:335-342.
50. Abbott A. Cell culture: biology's new dimension. Nature 2003, 424:870-872.
51. Friedrich J., Seidel C., Ebner R., Kunz-Schughart L.A. Spheroid-based drug screen: considerations and practical approach. Nat. Protoc. 2009, 4:309-324.
52. Hirschhaeuser F., Menne H., Dittfeld C., West J., Mueller-Klieser W., Kunz-Schughart L.A. Multicellular tumor spheroids: an underestimated tool is catching up again. J. Biotechnol. 2010, 148:3-15.
53. Yamada K.M., Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 2007, 130:601-610.
54. Friedrich J., Eder W., Castaneda J., Doss M., Huber E., Ebner R., Kunz-Schughart L.A. A reliable tool to determine cell viability in complex 3-d culture: the acid phosphatase assay. J. Biomol. Screen. 2007, 12:925-937.
55. Kunz-Schughart L.A., Freyer J.P., Hofstaedter F., Ebner R. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J. Biomol. Screen. 2004, 9:273-285.
56. Mueller-Klieser W. Tumor biology and experimental therapeutics. Crit. Rev. Oncol. Hematol. 2000, 36:123-139.